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Surveillance of patients at risk of developing hepatocellular carcinoma (HCC) relies on
ultrasound (US) examinations performed at 6-month intervals. Early detection of HCC on
a cirrhotic background is a challenging issue, since the US features of the different entities
in the multi-step process of hepatocarcinogenesis – such as low-grade and high-grade dys-
plastic nodule – do overlap. Contrast-enhanced US allows reliable detection of arterial neo-
angiogenesis associated with the malignant change. Several reports have shown that the
ability of contrast-enhanced US to diagnose HCC currently approaches that of optimised
multidetector computed tomography (CT) or dynamic magnetic resonance (MR) imaging
protocols. The use of contrast-enhanced US to characterise nodular lesions in cirrhosis
has recently been recommended by the clinical practice guidelines issued by the European
Federation of Societies for Ultrasound in Medicine and Biology and the American Associa-
tion for the Study of Liver Diseases. Contrast-enhanced US has also been successfully used
to assess response of HCC to image-guided percutaneous ablation procedures. In this arti-
cle, we discuss the advantages and limitations of contrast-enhanced US with respect to the
other imaging modalities in the setting of HCC.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Despite advances in computed tomography (CT) and mag-
netic resonance (MR) imaging, ultrasound (US) continues to
play a key role in the diagnostic management of hepatocellu-
lar carcinoma (HCC). According to the European Association
for the Study of the Liver (EASL) and the American Associa-
tion for the Study of Liver Diseases (AASLD), US is the recom-
mended tool for surveillance of patients at risk of developing
HCC.1,2 The introduction of US contrast agents and the
development of contrast-specific scanning techniques haveer Ltd. All rights reserved
of Diagnostic and
rsity Hospital, Via
8 6000 140; fax: +39
Lencioni).substantially increased the ability of US to detect and charac-
terise focal liver lesions as well as to assess tumour response
to image-guided percutaneous ablation procedures.3–5 Re-
cently, the European Federation of Societies for Ultrasound
in Medicine and Biology has issued recommendations for
the use of contrast agents in liver US, and the clinical practice
guideline of the AASLD has included contrast-enhanced US –
along with contrast-enhanced CT and contrast-enhanced MR
imaging – amongst the techniques that can be used for non-
invasive diagnosis of HCC in cirrhosis.2,6
2. Detection
Surveillance programmes aimed at early detection of HCC in
patients at risk are based on US examinations performed at
6–12 months intervals.1,2,7–11 Early detection of HCC, espe-
cially on a cirrhotic background, is a challenging issue. Liver.
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nodules. These features produce a coarse pattern on US, that
may impair identification of small tumours. Moreover, a com-
prehensive assessment of the liver parenchyma may some-
times be impossible because of the patient’s body habitus,
colonic interposition or morphologic changes induced by cir-
rhosis – such as retraction of the right liver lobe – that reduce
the ability to explore the liver via intercostal scans. The ability
to detect the emergence of a small HCC is highly dependent
on the expertise of the operator performing the examination
and the availability of state-of-the-art equipment. When
these requirements are met, surveillance has proved effective
in detecting HCC at an early stage.12,13,14,15 The value of US
surveillance performed in a primary care setting by operators
who do not have specific skills is questionable. If the expertise
is not available, the efficacy of surveillance will be lost. Upon
detection of a suspicious nodule, the recommended policy is
to evaluate the patient in referral centres with optimal human
and technical resources.1
Unfortunately, the use of contrast-enhanced US did not
prove beneficial in increasing the ability to detect small HCC
tumours. As a general rule, contrast-enhanced US techniques
are subject to the same limitations as any other US mode: if
the baseline scan is disappointing, the contrast-enhanced
US study will be disappointing as well.6 In addition, as de-
scribed later, the highest contrast between tumour and liver
parenchyma is seen during the short time of the arterial
phase. Whilst multidetector CT and dynamic MR sequences
can automatically image the entire liver parenchyma in a
few seconds, a comprehensive manual scanning of the whole
liver with US during the arterial phase is hardly possible, even
when performing repeated contrast injections. Thus, there is
currently no indication to use microbubble contrast agents to
increase the detection rate of HCC in patients undergoing US
surveillance.63. Characterisation
Carcinogenesis is often a multi-step process in liver cirrho-
sis. This process includes progression from cirrhotic nodule,
to macroregenerative nodule, to low-grade dysplastic
nodule (DN), to high-grade DN, to frank HCC.16 Progression
along the multi-step pathway is characterised by cytological
and architectural changes.17 Unfortunately, these entities
show variable and overlapping features at baseline US,
making reliable differential diagnosis impossible. Small
HCC may appear hyperechoic, hypoechoic or isoechoic with
respect to liver parenchyma, and is usually indistinguish-
able from a macroregenerative nodule or DN. In addition,
small hyperechoic HCC may be indistinguishable from a
hemangioma.18
One of the key pathologic factors for differential diagno-
sis between HCC and non-malignant hepatocellular lesions
that is reflected in imaging appearances is the vascular sup-
ply to the nodule. Through the progression from macrore-
generative nodule to low-grade DN, to high-grade DN, to
frank HCC, one sees loss of visualisation of portal tracts
and development of new arterial vessels, termed non-triadal
arteries, which become the dominant blood supply in overtHCC lesions.19,20,21 This arterial neoangiogenesis is the land-
mark of HCC and is the key for imaging diagnosis.22,23
Doppler US techniques have long been used in attempts
to evaluate tumour vascularity in HCC.24,25,26,27 At colour or
power Doppler US, a large HCC is usually displayed as a
vascular-rich lesion containing intratumoural flow signals
with an arterial Doppler spectrum. A basket pattern, which
is a fine blood-flow network surrounding the nodule, and
tumour vessels flowing into the lesion and branching with-
in it, are typically observed. Doppler interrogation shows a
pulsatile Doppler waveform with high frequency shifts
(>1 kHz) and abnormally elevated resistive index
(>0.71).25,27 In contrast, macroregenerative nodule and DN
either do not have any detectable intratumoural vascularity
or show arterial vessels with low frequency shifts and a
normal resistive index.28 However, in small HCC tumours,
the sensitivity of Doppler US in showing arterial neovascu-
larity is low, and abnormal flow can be demonstrated in
less than 50% of the lesions.24,28 In addition, the technique
is quite cumbersome and the positive predictive value is
not high.29
Several reports have shown that contrast-enhanced US is a
tool to show arterial neoangiogenesis in HCC.30,31,32,33 HCC
typically shows strong intratumoural enhancement in the
arterial phase, whilst macroregenerative nodule and DN usu-
ally do not show any early contrast uptake, and resemble the
enhancement pattern of liver parenchyma. The ability of con-
trast-enhanced US to show arterial hypervascularisation ap-
pears to approach that of optimised multidetector CT or
dynamic MR imaging protocols, provided that the nodule
can be clearly identified on baseline scans (Table 1). In one
study, in which only HCC tumours showing arterial hypervas-
cularity at CT were included, the sensitivity of contrast-en-
hanced US in the detection of arterial hyperenhancement
was 91%.34 In two comparative analyses including consecu-
tive patients with small nodules in cirrhosis detected during
surveillance, contrast-enhanced US was superior to multide-
tector CT and slightly inferior to dynamic MR imaging
in showing the presence of arterial hypervascularity
(Table 1).35,36
Unfortunately, the sole detection of arterial hypervascu-
larity in a small nodular lesion emerged in a cirrhotic liver
– although suspicious for HCC – may not be considered as
a conclusive finding. It is well established that non-malig-
nant hepatocellular lesions – especially high-grade DN –
may show arterial hypervascularisation on imaging.37,38
Small, high-flow hemangiomas may also appear as hyperen-
hancing nodule.39 A recent investigation has shown that in
the setting of cirrhotic patients undergoing surveillance, the
sole imaging finding of arterial hypervascularisation in
small solitary nodules of 2 cm or less has a specificity of
86% and a positive predictive value of 92% for the diagnosis
of HCC.36 To increase the specificity of imaging diagnosis, it
is mandatory to evaluate contrast wash-out during the por-
tal venous and the late phase, as recently recommended by
the 2005 EASL conference on HCC and the AASLD practice
guideline.2 Contrary to non-malignant entities, HCC is char-
acterised by rapid wash-out of the contrast agent, and usu-
ally appears hypoenhanced in the portal venous or the late
phase36,37,38 (Fig. 1).
Table 1 – Studies comparing contrast-enhanced US with multidetector CT or dynamic MR imaging in the ability to detect
arterial hypervascularisation in nodular lesions in cirrhosis
Author No. of lesions Lesion size Detection rate
Contrast US CT/MRI
Gaiani et al. 34 103 2.8 ± 1.3 cm 91% CT, 100%a
Bolondi et al. 35 41 1–2 cm 61% CT, 49%
31 2–3 cm 97% CT, 87%
Forner et al. 36 60 0.5–2 cm 78% MRI, 85%
a This series included only tumours showing arterial hypervascularity at multidetector at CT.
Fig. 1 – Non-invasive diagnosis of very-early HCC in cirrhosis. Contrast-enhanced US shows clear-cut enhancement in the
arterial phase (a) with rapid wash-out in the portal venous phase (b) in a 2-cm nodule in cirrhosis. The same findings
are observed on dynamic contrast-enhanced MR images obtained in the arterial phase (c) and the portal venous phase (d).
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arterial phase with wash-out in the portal venous or the
late phase – are used to diagnose HCC, the very high spec-
ificity that can be obtained has the downside of a reduced
sensitivity in the diagnosis of malignancy. In fact, the tim-
ing of contrast wash-out in HCC appears to be correlated
with the degree of tumour differentiation. Whilst moder-
ately or poorly differentiated tumours have fast contrast
wash-out and appear as defects in the portal venous orthe late phase, well-differentiated tumours may wash out
slowly and be iso-enhanced with respect to the liver paren-
chyma in the portal venous or the late phase.41,42,43 Thus,
diagnosis of small, well-differentiated tumours remains a
challenge. Nevertheless, this is the case for any dynamic
imaging technique, and the diagnostic accuracy of con-
trast-enhanced US for the diagnosis of HCC appears to be
similar to that of multidetector CT or dynamic MR imaging
(Table 2)36,40.
Table 2 – Studies comparing contrast-enhanced US with multidetector CT or dynamic MR imaging in the diagnosis of HCC
in nodules 2 cm or smaller detected during US surveillance
Author No. of patients No. of lesions Lesion size Sensitivity Specificity
Forner et al. 36 60 60a 0.5–2 cm
Contrast US 52% 93%
Dynamic MRI 62% 97%
Dai et al. 40 72 103 1–2 cm
Contrast US 91% 87%
Multidetector CT 80% 98%
Note. Figures refer to detection of typical enhancement pattern of HCC, i.e., arterial hypervascularizarion with venous wash-out.
a This series included only patients with solitary small tumours.
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Accurate intrahepatic staging is essential for the proper clin-
ical management of patients with HCC, particularly given the
propensity of HCC, even at early stages, to produce satellite
lesions via invasion of peripheral portal vein branches.
It is well established that US has limited sensitivity in the
detection of tiny satellite lesions. When careful imaging with
pathologic correlation on explanted livers was performed, the
sensitivity of US was as low as 14% in the detection of lesions
smaller than 2 cm, and as low as 0% for cancerous foci smal-
ler than 1 cm.44,45 Although these data have been collected
mainly in patients with advanced cirrhosis who underwent li-
ver transplantation (and therefore may not be applicable to
the general population of cirrhotic patients with HCC) the rate
of underestimation of the extent of the disease with US is
clearly unacceptable. Unfortunately, as discussed earlier, the
use of contrast agents did not result in any significant
improvement in the ability of US to detect small tumours.6
The duration of the arterial phase – during which HCC tu-
mours stand out against the faintly enhanced liver paren-
chyma – is far too short to allow a comprehensive manual
scanning of the entire organ. In the portal venous and the late
phase, contrary to hepatic metastases, the contrast between
tumour and liver is usually low, preventing identification of
small tumours not detected on baseline scans. Thus, even
in the era of contrast-enhanced US, the use of either multide-
tector CT or dynamic MR imaging for intrahepatic staging of
HCC is a mandatory step before therapeutic planning.23,46
In large HCC tumours, thrombosis of portal vein branches
due to tumour invasion is commonly observed on imaging.
However, in the setting of liver cirrhosis, portal vein thrombo-
sis has a prevalence of about 5%, even in the absence of
HCC.47 In patients with HCC, distinction between malignant
and non-malignant portal vein thrombosis is of paramount
importance, as vascular invasion determines the shift from
intermediate-stage to advanced-stage according to the Barce-
lona Clinic Liver Cancer (BCLC) staging system.48 Recent
observations have shown that contrast-enhanced US may
be a tool for this purpose.49,50 Unlike bland thrombosis, malig-
nant thrombi show the typical features of HCC, and demon-
strate rapid enhancement in the arterial phase due to the
presence of hypervascularized tumour tissue. In one study
including 54 consecutive patients who had cirrhosis, biopsy-
proven HCC, and thrombosis of the portal trunk or the main
right or left branches, contrast-enhanced US showed absolutespecificity and higher sensitivity than fine-needle biopsy in
demonstrating the malignant nature of the thrombus.49 In
another series of 34 patients listed for transplantation for
HCC on cirrhosis, who also showed thrombosis of the portal
trunk or intrahepatic branches, contrast-enhanced US was
able to accurately exclude the malignant nature of the throm-
bus, as confirmed by pathologic analysis of the explanted
organs.50
5. Diagnostic work-up
The detection of a nodular lesion during US surveillance
should always raise the suspicion of HCC.1,2 However, patho-
logic studies have shown that a significant proportion of
small nodules detected by US in cirrhotic livers do not corre-
spond to HCC, but rather to non-malignant hepatocellular
nodules. Percutaneous US-guided biopsy might be considered
as the most straightforward approach to differentiate HCC
from non-malignant hepatocellular lesions. Unfortunately,
biopsy of small nodular lesions in cirrhosis is not entirely reli-
able. In fact, needle placement may be difficult and a sam-
pling error may occur. Moreover, it is very difficult to
distinguish well-differentiated HCC from DN on small biopsy
specimens, as there is no clear-cut dividing line between dys-
plasia and a well-differentiated tumour.51 Therefore, a posi-
tive biopsy, as assessed by an expert pathologist, is helpful,
but a negative biopsy can never rule out malignancy.1,2 In
addition, biopsy is associated with a low but not negligible
rate of complications, including tumour seeding along the
needle track.
Both the 2005 EASL conference on HCC and the AASLD
practice guideline have recommended that further investiga-
tion of nodules detected during US surveillance with dynamic
imaging techniques, including contrast-enhanced US, multi-
detector CT, or dynamic MR imaging, is required to highlight
the different vascular supply of HCC as compared to non-
malignant entities.2 However, the diagnostic protocol should
be structured according to the actual risk of malignancy and
the possibility of achieving a reliable diagnosis. Since the
prevalence of HCC amongst US-detected nodules is strongly
related to the size of the lesion, the diagnostic work-up de-
pends on the size of the lesion.2 Lesions smaller than 1 cm
in diameter have a low likelihood of being HCC. However,
such minute nodules may become malignant with time.
Therefore, these lesions need to be followed up in order to
detect growth suggestive of malignant transformation. A
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lesion grows to more than 1 cm, at which point additional
diagnostic techniques are applied.1,2 It has to be emphasized,
however, that the absence of growth during the follow-up
period does not rule out the malignant nature of the nodule
because an early HCC may occasionally take more than 1 year
to increase in size.1
When the nodule exceeds 1 cm in size, the lesion is more
likely to be HCC and diagnostic confirmation should be pur-
sued. It is accepted that the diagnosis of HCC can be made
without biopsy in a lesion larger than 1 cm that shows char-
acteristic vascular features of HCC – i.e. arterial hypervascu-
larisation with wash-out in the portal venous or the late
phase –even in patients with normal alpha-fetoprotein value.2
In lesions above 2 cm a single imaging technique showing the
characteristic vascular profile of HCC mentioned above may
confidently establish the diagnosis. In lesions ranging be-
tween 1 and 2 cm, AASLD guidelines recommend that typical
imaging findings confirmed by two coincident dynamic imag-
ing modalities to allow a non-invasive diagnosis are re-
quired.2 Such lesions ranging between 1 and 2 cm are the
true target of screening programmes, as they identify the pop-
ulation of patients with very-early HCC tumours, who have
the highest likelihood for cure with surgical resection or per-Fig. 2 – Percutaneous ablation of HCC. Multidetector CT image a
arterially enhancing viable tumour (a). Contrast-enhanced US c
enhancing nodule within the non-enhancing coagulated tumou
residual disease is easily achieved (c) and additional treatmentcutaneous ablation.52 Specificity of imaging diagnosis is cru-
cial to prevent therapeutic mistakes due to a false positive
diagnosis of malignancy.
The combination of contrast-enhanced US and multide-
tector CT (or contrast-enhanced US and dynamic MR imaging)
appears the most reliable for non-invasive diagnosis of small
tumours. This is clearly the most cost-effective combination,
as the contrast-enhanced US study can be performed imme-
diately upon detection of a focal lesion at baseline US, and
only one additional examination (either CT or MR imaging)
is needed as a confirmatory test. In addition, given the differ-
ent pharmacokinetics of US contrast agents (blood-pool com-
pounds) with respect to CT and MR imaging contrast agents
(extracellular fluid space compounds), such combination pro-
vides complementary information. In a prospective validation
of AASLD criteria conducted in a series of consecutive pa-
tients with a solitary focal lesion smaller than 2 cm detected
during US surveillance, the combined use of contrast-en-
hanced US and dynamic MR imaging achieved 100% specific-
ity for the diagnosis of HCC.36
If the lesion does not show typical features of HCC, or the
vascular profile does not coincide with the imaging tech-
niques, biopsy is recommended.2 It is important to point out
that the absence of arterial hypervascularisation on imagingcquired after RF ablation shows small focus of residual,
learly shows the area of residual disease as clear-cut
r (b). Precise real-time needle targeting of the tiny area of
with ethanol injection is administered (d).
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at a very early stage may not exhibit the characteristic vascu-
lar features of overt HCC.35 Delaying the diagnosis of HCC until
imaging detection of arterial hypervascularisation occurs
could reduce the chances of radical cure, since the incidence
of microscopic vascular invasion and satellite nodules signifi-
cantly increases when the tumour exceeds 2 cm and develops
imaging-detectable neoangiogenesis.17 In the setting of cir-
rhotic patients in whom a solitary nodule smaller than 2 cm
is detected during US surveillance, biopsy is still needed in
about two-thirds of the cases, and, given the well-known
limitations of pathology interpretation, repeated biopsies are
needed in as many as 30% of the cases.36 This is the area where
advances in imaging techniques based on liver-specific con-
trast agents (including hepatocyte-targeted agents and reticu-
loendothelial system-targeted agents) should be further
investigated53 and research on new diagnostic tools – based
on immunostaining, gene expression assessment, or protein
profiling – should be focussed.546. Response to image-guided ablation
Image-guided percutaneous ablation is currently accepted as
the best therapeutic choice for non-surgical treatment of
early-stage HCC.1,2 Over the past two decades, several meth-
ods for chemical ablation or thermal tumour destruction
through localised heating or freezing have been developed
and clinically tested. Radiofrequency (RF) ablation is currently
established as the primary ablative modality at most institu-
tions on the basis of a more consistent local tumour
control.55,56,57,58 US is an ideal tool to guide percutaneous
ablation as it allows real-time monitoring of the procedure.
When US is used as the imaging modality for guiding
ablations, the addition of contrast agent can provide addi-
tional important information. Firstly, it improves delineation
and conspicuity of lesions poorly visualised on baseline scans
thus facilitating targeting; secondly it allows immediate
assessment of the outcome of treatment by showing disap-
pearance of any previously visualised intralesional enhance-
ment; and finally it may be useful in the follow-up protocol
for early detection of local tumour recurrence.6
Contrast-enhanced images obtained shortly after treat-
ment demonstrate successful ablation as a non-enhancing
area with or without a peripheral enhancing rim. The
enhancing rim that may be observed along the periphery of
the ablation zone appears as a relatively concentric, symmet-
ric and uniform process in an area with smooth inner mar-
gins. This is a transient finding that represents reactive
hyperemia and needs to be differentiated from irregular
peripheral enhancement due to residual tumour that occurs
at the treatment margin. In contrast to benign peri-ablational
enhancement, residual unablated tumour often grows in
scattered, nodular or eccentric patterns (Fig. 2).
Later follow-up imaging studies should be aimed not
only at detecting the recurrence of the treated lesion but
also the development of new hepatic lesions or the emer-
gence of extrahepatic disease. Contrast-enhanced CT or
MR imaging are recognised as the standard modalities in
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